Efficacy and safety of perospirone as adjunctive therapy in major depressive disorder patients with inadequate response to antidepressants: a randomized clinical trial
The study was supported by the STI2030-Major Projects (grant 2021ZD0202000), National Natural Science Foundation of China (grant 82201693 and 82471555), Hunan Provincial Natural Science Outstanding Youth Foundation (grant 2025JJ20093), Science and Technology Innovation Program of Hunan Province (grant 2024RC3057), Sanming Project of Medicine in Shenzhen (grant SZSM202311025), and Reboscience (Zhuhai) Pharmaceutical Research Co., Ltd., and sponsored by Livzon Pharmaceutical Group Inc.
Institutions
- Fujian Medical University (CN)
- Central South University (CN)
- Shanxi Medical University (CN)
- Peking University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- Nanjing Brain Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Beijing HuiLongGuan Hospital (CN)
- Hebei Mental Health Center (CN)
- Zigong First People's Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Nanjing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103626
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Sanming Project of Medicine in Shenzhen